The Numbers
After a 40-year research blackout, psychedelic science has re-emerged with methodological rigor that was absent from 1960s studies. The results are among the most striking in modern psychiatry.
The Mystical Experience
The Johns Hopkins group didn't set out to study spirituality. They set out to study psilocybin as a therapeutic agent. What they found was that the drug reliably produces something that researchers — including skeptical neuroscientists — call mystical experience. The Mystical Experience Questionnaire (MEQ30) measures it.
Unity — internal and external
A sense of merging with the totality of everything — loss of the felt boundary between self and world. Subjects describe this not as a thought about unity but as a direct perception of it. Distinct from simple feelings of connectedness.
Noetic quality
The sense that what is being experienced is not hallucination but genuine knowledge — a perception of ultimate reality. Subjects persistently insist, long after the experience, that "it was more real than ordinary reality." This is one of the most consistent and puzzling features.
Sacredness
A sense of encountering something holy, divine, or of ultimate importance. This occurs across atheists, agnostics, and believers — it is not simply a reflection of prior religious belief. Atheist subjects often describe it as "the most religious experience of my life."
Deeply felt positive mood
Joy, love, peace, and awe at a depth subjects report having never experienced previously. Not euphoria in the hedonic sense — subjects describe a profound okayness that persists for months after the session.
Transcendence of time and space
Loss of usual sense of location in time and space. Some subjects describe perceiving all moments of their life simultaneously, or experiencing timelessness. The parallel to NDE life review reports is noted by multiple researchers.
Ineffability
The persistent sense that the experience cannot be adequately described in language. Not vagueness — subjects feel they experienced something specific and real that human language lacks the vocabulary to convey. This is reported universally, regardless of the subject's articulacy.
Landmark Studies
The first rigorous modern replication of Walter Pahnke's 1962 Good Friday Experiment. 36 participants with no prior hallucinogen experience received either psilocybin or Ritalin (active placebo) in a double-blind design. 22 of 36 psilocybin sessions produced complete mystical experiences by MEQ30 criteria. Two-thirds rated it among their top five most meaningful life experiences. Effects on personality openness persisted at 14-month follow-up. Published in Psychopharmacology, 2006.
Two simultaneous randomized controlled trials examined psilocybin in cancer patients with significant death anxiety. Both found substantial, rapid reductions in depression, anxiety, and fear of death — with 80% maintaining clinically significant improvements at 6-month follow-up. Notably, the intensity of the mystical experience (MEQ30 score) directly predicted therapeutic outcome. The mechanism appeared to be a fundamental shift in relationship to mortality, not simply symptom suppression.
Strassman's clinical research with intravenous DMT — the first psychedelic research approved in the U.S. after the moratorium — found that a significant proportion of subjects reported encounters with discrete non-human entities. A 2020 Johns Hopkins survey of 2,561 adults who had experienced DMT entities found that 99% rated the encounter as real or realer than ordinary reality. 80% described it as benevolent. 30% said it changed their beliefs about consciousness and death. The consistency and realism of these encounters is unexplained by current neuroscience.
Phase 3 clinical trials of MDMA-assisted therapy for PTSD produced response rates significantly exceeding current standard-of-care treatments. 67% of MDMA recipients no longer met PTSD diagnostic criteria after three sessions, compared to 32% in the placebo group. While MDMA is not a classic psychedelic, the therapeutic mechanism involves altered states of consciousness, reduced fear response, and what subjects describe as accessing experiences with a different emotional valence — relevant to understanding how altered states produce lasting change.
The Connection to Soul Science
Common mechanism?
If psychedelics and near-death states produce similar experiences, they may share a common mechanism — one that accesses states of consciousness that are not produced by, but filtered by, the default brain. This is the filter theory of consciousness applied to pharmacology.
Endogenous DMT
DMT is produced by the human body. Strassman and others have speculated that it may be released in elevated quantities at death — potentially explaining the pharmacology of NDEs. This remains speculative; the evidence for elevated DMT at death is limited but not absent.
Therapeutic death anxiety
The most robust finding — psilocybin substantially reduces fear of death — is itself relevant. The therapeutic mechanism appears to be experiential: subjects feel they have touched something beyond ordinary ego-bound existence. Whether that something is "real" is a question psychedelic science hasn't yet asked.
The entity question
DMT entity encounters are the most philosophically challenging finding in modern psychedelic research. If the entities are simply produced by the brain, why do they behave as independent agents, convey unexpected information, and appear to subjects as more real than reality? This is unanswered.
Key Researchers
Go deeper with the research AI
Ask about specific studies, the phenomenology of mystical states, DMT entity encounters, or the NDE connection.
Ask ReincarnatedAI →